Article
Antisense technology: A review
1 Jan 2021
Abstract excerpt
Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs) have now been approved for commercial use, and the ASOs in phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases. In fact, two ASOs are used in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
